X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs LUPIN LTD - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD LUPIN LTD STRIDES SHASUN LTD/
LUPIN LTD
 
P/E (TTM) x 14.0 16.6 84.2% View Chart
P/BV x 1.9 3.9 48.9% View Chart
Dividend Yield % 0.6 0.8 69.2%  

Financials

 STRIDES SHASUN LTD   LUPIN LTD
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-16
LUPIN LTD
Mar-16
STRIDES SHASUN LTD/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,4132,127 66.4%   
Low Rs8481,294 65.5%   
Sales per share (Unadj.) Rs353.3304.1 116.2%  
Earnings per share (Unadj.) Rs23.450.4 46.4%  
Cash flow per share (Unadj.) Rs41.060.7 67.5%  
Dividends per share (Unadj.) Rs5.007.50 66.7%  
Dividend yield (eoy) %0.40.4 100.9%  
Book value per share (Unadj.) Rs320.4243.8 131.4%  
Shares outstanding (eoy) m89.35450.58 19.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.25.6 56.9%   
Avg P/E ratio x48.333.9 142.4%  
P/CF ratio (eoy) x27.628.2 97.8%  
Price / Book Value ratio x3.57.0 50.3%  
Dividend payout %21.414.9 143.7%   
Avg Mkt Cap Rs m100,988770,740 13.1%   
No. of employees `0004.716.4 28.7%   
Total wages/salary Rs m4,98821,077 23.7%   
Avg. sales/employee Rs Th6,730.08,379.6 80.3%   
Avg. wages/employee Rs Th1,063.61,289.0 82.5%   
Avg. net profit/employee Rs Th445.51,388.7 32.1%   
INCOME DATA
Net Sales Rs m31,564137,016 23.0%  
Other income Rs m1,2121,877 64.6%   
Total revenues Rs m32,776138,893 23.6%   
Gross profit Rs m5,21337,535 13.9%  
Depreciation Rs m1,5734,635 33.9%   
Interest Rs m1,803446 404.1%   
Profit before tax Rs m3,04934,330 8.9%   
Minority Interest Rs m127-88 -144.5%   
Prior Period Items Rs m-270-   
Extraordinary Inc (Exp) Rs m-3710-   
Tax Rs m68911,536 6.0%   
Profit after tax Rs m2,08922,707 9.2%  
Gross profit margin %16.527.4 60.3%  
Effective tax rate %22.633.6 67.2%   
Net profit margin %6.616.6 39.9%  
BALANCE SHEET DATA
Current assets Rs m35,94997,790 36.8%   
Current liabilities Rs m19,40253,872 36.0%   
Net working cap to sales %52.432.1 163.6%  
Current ratio x1.91.8 102.1%  
Inventory Days Days7185 83.7%  
Debtors Days Days127121 104.6%  
Net fixed assets Rs m34,47886,379 39.9%   
Share capital Rs m894901 99.1%   
"Free" reserves Rs m22,601105,735 21.4%   
Net worth Rs m28,632109,844 26.1%   
Long term debt Rs m27,45553,739 51.1%   
Total assets Rs m76,591224,378 34.1%  
Interest coverage x2.777.9 3.5%   
Debt to equity ratio x1.00.5 196.0%  
Sales to assets ratio x0.40.6 67.5%   
Return on assets %5.110.3 49.3%  
Return on equity %7.320.7 35.3%  
Return on capital %8.221.2 38.5%  
Exports to sales %48.149.1 98.1%   
Imports to sales %14.57.4 194.3%   
Exports (fob) Rs m15,19267,244 22.6%   
Imports (cif) Rs m4,56510,199 44.8%   
Fx inflow Rs m16,61271,405 23.3%   
Fx outflow Rs m5,29217,807 29.7%   
Net fx Rs m11,32053,598 21.1%   
CASH FLOW
From Operations Rs m717-3,690 -19.4%  
From Investments Rs m-22,284-69,434 32.1%  
From Financial Activity Rs m29,48858,126 50.7%  
Net Cashflow Rs m8,073-14,998 -53.8%  

Share Holding

Indian Promoters % 27.7 46.6 59.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 37.8 11.3 334.5%  
FIIs % 8.6 31.9 27.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 10.1 256.4%  
Shareholders   56,241 98,259 57.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  UNICHEM LAB  

Compare STRIDES SHASUN LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Aug 18, 2017 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 5-YR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS